UBS Global Healthcare Conference - NATERA INC

Financial Performance:

• Current revenue run rate exceeds $3 billion; MRD (Signatera) is projected to generate slightly over $1 billion in revenue for the current year.
• Average Selling Price (ASP) stands at approximately $1,290, with contracted rates in the mid-$3,000s; goal is to reach an indicative $1,450 ASP by 2029 via expanded Medicare reimbursement.
• Revenue volume grew by 113,000 units year-over-year (record growth), representing a sequential increase of ~33,113 units.
• Operating expenses (OPEX) are expected to rise 12% next year, primarily driven by a ~$950 million R&D budget, with ~70% of R&D spend allocated to CRC screening and early cancer detection (non-revenue generating currently).
• Cash flow dynamics are stable following the 2024 cash flow break-even target; no specific cash flow guidance provided for future years other than the path to the 2029 revenue target.

Guidance and Future Outlook:

• Announced a long-term revenue target of $6 billion by 2029, representing a doubling of current revenue.
• The 2029 target is described as "eminently achievable" and does not rely on immediate revenue contributions from CRC screening or MSED, but rather on compounding Signatera volumes and ASP growth.
• Outlook indicates a "double T.A.M." opportunity once Early Cancer Detection (CRC and MSED) programs mature, potentially doubling the addressable market size by the end of the decade.
• Expected timeline for CRC screening: Clinical data readout (FIND study) in the second half of 2025, FDA submission and approval process (~9 months), and US launch estimated for late 2028 to early 2029.
• MSED (Multi-Modal Screening) strategy is path-dependent on CRC results but aims for rapid technology application and launch following CRC approval.
• Japan launch is targeted with pricing discussions ongoing, expecting launch announcement by the J.P. Morgan conference in January 2025.

Business Segments and Product Lines:

• Signatera (MRD): The core growth engine; expanding from targeted tumor types (breast, colorectal) to a "liquid CT scan" model covering broader SEER data tumor mixes.
• CRC Screening (FIND Study): Currently in late-stage enrollment; aims to establish a new standard of care for colorectal cancer screening in high-risk populations.
• MSED: Next-generation multi-modal early detection platform expected to build on CRC learnings.
• Japan Expansion: Significant growth potential leveraging existing guidelines and KOL relationships; considered a near-term expansion milestone.
• Commercial Scale: Sales force is at a natural ceiling of ~300-400 reps for the current MRD market to optimize efficiency; further expansion expected to be minimal or strategic rather than linear.

Market and Competitive Landscape:

• MRD is identified as an emerging industry vertical with a Total Addressable Market (TAM) estimated between $15 billion and $30 billion; current penetration is single-digit.
• Natera holds a leadership position, having established dominance in reproductive health before pivoting to and dominating the MRD space.
• Market trends indicate a shift toward liquid biopsy as a standard of care; Natera views itself as uniquely positioned due to deep scientific and commercial integration.
• Competitive advantage cited includes collaborative decision-making culture, long-tenured leadership, and a proven track record of clinical trial execution (e.g., Japanese data leading to strong colorectal outcomes).

Risks and Challenges:

• Reimbursement: Continued dependency on Medicare and commercial payer coverage expansion; lack of coverage for certain tumor types limits ASP maximization.
• Regulatory Timelines: FDA approval for CRC screening remains a critical path risk; launch timeline is dependent on data readouts and regulatory review periods.
• R&D Investment: High current R&D spend on non-revenue generating programs (CRC, MSED) creates a "boat anchor" on near-term profitability metrics.
• Market Saturation: Potential natural ceiling to the US commercial team size relative to the number of oncologists (approx. 11,000).

Management Commentary and Tone:

• Leadership Transition: Steve Olson (CEO) is succeeded by Solomon Solomon, a 13-year veteran and key architect of Signatera's strategy; transition is immediate with no six-month overlap to ensure clarity and continuity.
• Tone: Management expresses high confidence ("bullish") on execution, citing a collaborative culture where sales and science teams operate with equal influence.
• Strategic Philosophy: Emphasis on "under-promise and over-deliver," using the $6B goal as a "rallying cry" for employees rather than a rigid contract.
• Commercial Execution: Reiterated belief that profitability will naturally increase as R&D spending scales and Signatera benefits from compounding repeat testing, without needing a 2,000-person sales force.

Analyst Questions and Answers:

• Q: Concerns over CEO transition and loss of commercial expertise.
  • A: Management emphasized that the commercial team is a collective success of a decade of collaboration; Solomon is trusted by the sales force, and the transition is seamless due to Solomon's deep existing involvement in commercial strategy.
• Q: Is the $6B target achievable without heroic growth rates?
  • A: Yes, the model relies on steady compounding of existing Signatera patients and moderate ASP growth, avoiding the need for "heroic" acceleration or immediate revenue from early cancer detection.
• Q: Why the immediate transition rather than a 6-month handover?
  • A: A prolonged transition was deemed dysfunctional; Solomon was already chairing key meetings and making core decisions, so an immediate handover provided necessary organizational clarity.
• Q: Details on the sequential growth metrics (33k units).
  • A: CFO clarified that year-over-year growth is now the more relevant metric for a business at this scale; sequential fluctuations are less meaningful than the clear YOY acceleration.

Other Key Points:

• Culture: Natera boasts a leadership team with 10-15 years of tenure, fostering a unique "friends and colleagues" dynamic that drives rapid decision-making and consensus.
• Employee Engagement: Long-term goals are used internally to engage employees as partners, similar to the culture built around the 2024 cash flow break-even target.
• Clinical Data: Preliminary prospective PROCEED study data on 2,000 patients has informed the development of the final assay for CRC screening.
• Global Expansion: Japan is highlighted as a critical market for colorectal MRD, with long-term outcomes data already validating the technology there.